Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease

Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease

Alzheimer's disease (AD), a chronic neurodegenerative disease, is clinically characterized by loss of memory and learning ability among other neurological deficits. Amyloid plaques, hyperphosphorylated tau protein, and neurofibrillary tangles involve in AD etiology. Meanwhile, enzymes and their...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zahra Farajzadeh Vahid, Morteza Eskandani, Hamed Dadashi, Somayeh Vandghanooni, Mohammad-Reza Rashidi
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Heliyon
Subjects:	Alzheimer's disease Beta amyloid Target enzymes Inhibitors of enzymes Clinical studies Multi-target drugs
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844024167874
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
by: Linda J. Van Eldik, et al.
Published: (2024-10-01)

GABA Signaling in Spatial Memory changes in Animal Model of Alzheimer’s disease
by: Bahareh Tavakoli-Far, et al.
Published: (2024-08-01)

Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge
by: Shahram Darabi, et al.
Published: (2025-06-01)

Neuroprotective effect of ranolazine in mice's model of Alzheimer's disease
by: Mariam H. Sadiq, et al.
Published: (2024-06-01)

Novel targets for the treatment and prevention of Alzheimer's disease in the European population, inspiration from amyloid beta and tau protein
by: Xifeng Wang, et al.
Published: (2024-10-01)

Determination of Intestinal Enzyme Activities During Infancy Period
by: Emel Örün, et al.
Published: (2016-08-01)

Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease
by: Xiaoming Qi, et al.
Published: (2024-11-01)

SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer’s disease
by: Mridula Bhalla, et al.
Published: (2025-01-01)

Deciphering the Role of Adrenergic Receptors in Alzheimer’s Disease: Paving the Way for Innovative Therapies
by: Androulla N. Miliotou, et al.
Published: (2025-01-01)

Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites
by: Felix S. Meier‐Stephenson, et al.
Published: (2022-01-01)

Molecular Mechanisms of Alzheimer’s Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy
by: Eun Hee Ahn, et al.
Published: (2025-01-01)

REELIN ameliorates Alzheimer's disease, but how?
by: Yu Katsuyama, et al.
Published: (2024-11-01)

Advances in Alzheimer’s disease therapeutics: biochemistry, exploring bioactive compounds and novel approaches
by: Ayomide Victor Atoki, et al.
Published: (2023-09-01)

Alzheimer's disease drug development in an evolving therapeutic landscape
by: Stacie Weninger, et al.
Published: (2024-10-01)

New Insights into the Development of Donepezil-Based Hybrid and Natural Molecules as Multi-Target Drug Agents for Alzheimer’s Disease Treatment
by: Violina T. Angelova, et al.
Published: (2024-11-01)

Choosing the Right Angiotensin Converting Enzyme Inhibitors; Gender –Specific Approach
by: Neena Elsa Varghese, et al.
Published: (2024-12-01)

Xixin Decoction’s novel mechanism for alleviating Alzheimer’s disease cognitive dysfunction by modulating amyloid-β transport across the blood–brain barrier to reduce neuroinflammation
by: Chaokai Yang, et al.
Published: (2025-01-01)

A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potential
by: Susan A. Greenfield, et al.
Published: (2022-01-01)

Retrospective evaluation of risk factors for worsening renal function after angiotensin‐converting enzyme inhibitor treatment in dogs
by: Yelim Lee, et al.
Published: (2025-01-01)

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
by: Amin Mahmood Thawabteh, et al.
Published: (2024-10-01)

Novel small molecule-based acetylcholinesterase (AChE) inhibitors: From biological perspective to recent developments
by: Anjali Sobha, et al.
Published: (2024-12-01)

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model
by: Roxana Aldea, et al.
Published: (2022-01-01)

Dietary Strategies to Mitigate Alzheimer’s Disease: Insights into Antioxidant Vitamin Intake and Supplementation with Microbiota–Gut–Brain Axis Cross-Talk
by: Wan Zurinah Wan Ngah, et al.
Published: (2024-12-01)

Disentangling tau and brain atrophy cluster heterogeneity across the Alzheimer's disease continuum
by: Jon B. Toledo, et al.
Published: (2022-01-01)

Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
by: Alexandra Wicker, et al.
Published: (2024-10-01)

Suppression of MT5-MMP Reveals Early Modulation of Alzheimer’s Pathogenic Events in Primary Neuronal Cultures of 5xFAD Mice
by: Dominika Pilat, et al.
Published: (2024-12-01)

Therapeutic agents for Alzheimer’s disease: a critical appraisal
by: Marta Weinstock
Published: (2024-12-01)

Role of Graphene Oxide in Disentangling Amyloid Beta Fibrils
by: Brianna Duswalt, et al.
Published: (2024-10-01)

AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery
by: Frances M. Potjewyd, et al.
Published: (2022-01-01)

Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A<sup>+</sup>T<sup>+</sup> (A<sup>+</sup>T<sub>1</sub><sup>+</sup>) Alzheimer’s Disease
by: Ioanna Tsantzali, et al.
Published: (2024-12-01)

Blood-based biomarkers and plasma Aβ assays in the differential diagnosis of Alzheimer’s disease and behavioral-variant frontotemporal dementia
by: Pablo Mohaupt, et al.
Published: (2024-12-01)

OATP1A2 mediates Aβ1-42 transport and may be a novel target for the treatment of Alzheimer’s disease
by: Jinhua Wen, et al.
Published: (2024-11-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review
by: Cyrus Jalili, et al.
Published: (2023-05-01)

Effects of the therapeutic correction of U1 snRNP complex on Alzheimer’s disease
by: Caio Bruno Q. S. Leal, et al.
Published: (2024-12-01)

Marital dissolution and cognition: The mediating effect of Aβ neuropathology
by: Avinash Chandra, et al.
Published: (2024-10-01)

Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
by: Eliasz Engelhardt, et al.
Published: (2024-12-01)

Diagnosis and Treatment of Alzheimer’s Disease: Current Update
by: Younghee Yim, et al.
Published: (2025-01-01)

A molecular dynamics investigation into the inhibitory function of hydroxypropyl-beta-cyclodextrin (HPBCD) in its interaction with amyloid-beta (Aβ) plaques near the cell membrane in the context of Alzheimer's disease.
by: Morteza Rezaeisadat, et al.
Published: (2024-12-01)

Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease
by: William Kielbasa, et al.
Published: (2024-10-01)